|
SYMPATHOMIMETICS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
ISOPROTERENOL SHOULD NOT BE GIVEN WITH OTHER BETA AGONIST OR SYMPATHOMIMETICS BECAUSE OF INCREASED SIDE EFFECTS
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CO-ADMINISTRATION OF DIGOXIN AND SYMPATHOMIMETICS INCREASES THE RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF DIGOXIN AND SYMPATHOMIMETICS INCREASES THE RISK OF CARDIAC ARRHYTHMIAS
|
TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
NON POTASSIUM SPARING DIURETICS MAY CAUSE UNPRECEDENTED HYPOKALEMIA
|
NON POTASSIUM SPARING DIURETICS MAY CAUSE UNPRECEDENTED HYPOKALEMIA
|
NON POTASSIUM SPARING DIURETICS MAY CAUSE UNPRECEDENTED HYPOKALEMIA
|
NON POTASSIUM SPARING DIURETICS MAY CAUSE UNPRECEDENTED HYPOKALEMIA
|
|
CO-ADMINISTRATION MAY CAUSE INCREASE IN BLOOD PRESSURE
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE DRUG
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
BETABLOCKERS NOT ONLY BLOCK THE PULMONARY EFFECTS OF BETA-AGONISTS LIKE ALBUTEROL BUT MAY PRODUCE SEVERE BRONCHOSPASM IN ASTHMATICS
|
BETABLOCKERS NOT ONLY BLOCK THE PULMONARY EFFECTS OF BETA-AGONISTS LIKE ALBUTEROL BUT MAY PRODUCE SEVERE BRONCHOSPASM IN ASTHMATICS
|
BETABLOCKERS NOT ONLY BLOCK THE PULMONARY EFFECTS OF BETA-AGONISTS LIKE ALBUTEROL BUT MAY PRODUCE SEVERE BRONCHOSPASM IN ASTHMATICS
|
BETABLOCKERS NOT ONLY BLOCK THE PULMONARY EFFECTS OF BETA-AGONISTS LIKE ALBUTEROL BUT MAY PRODUCE SEVERE BRONCHOSPASM IN ASTHMATICS
|
BETABLOCKERS NOT ONLY BLOCK THE PULMONARY EFFECTS OF BETA-AGONISTS LIKE ALBUTEROL BUT MAY PRODUCE SEVERE BRONCHOSPASM IN ASTHMATICS
|
BETABLOCKERS NOT ONLY BLOCK THE PULMONARY EFFECTS OF BETA-AGONISTS LIKE ALBUTEROL BUT MAY PRODUCE SEVERE BRONCHOSPASM IN ASTHMATICS
|
BETABLOCKERS NOT ONLY BLOCK THE PULMONARY EFFECTS OF BETA-AGONISTS LIKE ALBUTEROL BUT MAY PRODUCE SEVERE BRONCHOSPASM IN ASTHMATICS
|
BETABLOCKERS NOT ONLY BLOCK THE PULMONARY EFFECTS OF BETA-AGONISTS LIKE ALBUTEROL BUT MAY PRODUCE SEVERE BRONCHOSPASM IN ASTHMATICS
|
BETABLOCKERS NOT ONLY BLOCK THE PULMONARY EFFECTS OF BETA-AGONISTS LIKE ALBUTEROL BUT MAY PRODUCE SEVERE BRONCHOSPASM IN ASTHMATICS
|
BETABLOCKERS NOT ONLY BLOCK THE PULMONARY EFFECTS OF BETA-AGONISTS LIKE ALBUTEROL BUT MAY PRODUCE SEVERE BRONCHOSPASM IN ASTHMATICS
|
BETABLOCKERS NOT ONLY BLOCK THE PULMONARY EFFECTS OF BETA-AGONISTS LIKE ALBUTEROL BUT MAY PRODUCE SEVERE BRONCHOSPASM IN ASTHMATICS
|
BETABLOCKERS NOT ONLY BLOCK THE PULMONARY EFFECTS OF BETA-AGONISTS LIKE ALBUTEROL BUT MAY PRODUCE SEVERE BRONCHOSPASM IN ASTHMATICS
|
BETABLOCKERS NOT ONLY BLOCK THE PULMONARY EFFECTS OF BETA-AGONISTS LIKE ALBUTEROL BUT MAY PRODUCE SEVERE BRONCHOSPASM IN ASTHMATICS
|
BETABLOCKERS NOT ONLY BLOCK THE PULMONARY EFFECTS OF BETA-AGONISTS LIKE ALBUTEROL BUT MAY PRODUCE SEVERE BRONCHOSPASM IN ASTHMATICS
|
BETABLOCKERS NOT ONLY BLOCK THE PULMONARY EFFECTS OF BETA-AGONISTS LIKE ALBUTEROL BUT MAY PRODUCE SEVERE BRONCHOSPASM IN ASTHMATICS
|
BETABLOCKERS NOT ONLY BLOCK THE PULMONARY EFFECTS OF BETA-AGONISTS LIKE ALBUTEROL BUT MAY PRODUCE SEVERE BRONCHOSPASM IN ASTHMATICS
|
BETABLOCKERS NOT ONLY BLOCK THE PULMONARY EFFECTS OF BETA-AGONISTS LIKE ALBUTEROL BUT MAY PRODUCE SEVERE BRONCHOSPASM IN ASTHMATICS
|
BETABLOCKERS NOT ONLY BLOCK THE PULMONARY EFFECTS OF BETA-AGONISTS LIKE ALBUTEROL BUT MAY PRODUCE SEVERE BRONCHOSPASM IN ASTHMATICS
|
BETABLOCKERS NOT ONLY BLOCK THE PULMONARY EFFECTS OF BETA-AGONISTS LIKE ALBUTEROL BUT MAY PRODUCE SEVERE BRONCHOSPASM IN ASTHMATICS
|
BETABLOCKERS NOT ONLY BLOCK THE PULMONARY EFFECTS OF BETA-AGONISTS LIKE ALBUTEROL BUT MAY PRODUCE SEVERE BRONCHOSPASM IN ASTHMATICS
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INCREASED RISK OF HYPOKALEMIA
|
INCREASED RISK OF HYPOKALEMIA
|
INCREASED RISK OF HYPOKALEMIA
|
INCREASED RISK OF HYPOKALEMIA
|
INCREASED RISK OF HYPOKALEMIA
|
INCREASED RISK OF HYPOKALEMIA
|
INCREASED RISK OF HYPOKALEMIA
|
INCREASED RISK OF HYPOKALEMIA
|
INCREASED RISK OF HYPOKALEMIA
|
INCREASED RISK OF HYPOKALEMIA
|
INCREASED RISK OF HYPOKALEMIA
|
INCREASED RISK OF HYPOKALEMIA
|
INCREASED RISK OF HYPOKALEMIA
|
INCREASED RISK OF HYPOKALEMIA
|
INCREASED RISK OF HYPOKALEMIA
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|